- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05704790
Feasibility and Acceptability of Brief, Telehealth Cognitive Compensatory Training for Pediatric Cancer Patients
February 28, 2024 updated by: University of Michigan Rogel Cancer Center
Feasibility and Acceptability of Brief, Telehealth Cognitive Compensatory Training for Children Treated for Pediatric Cancer
This pilot study will be a prospective, single arm study to investigate the feasibility and acceptability of a brief, telehealth, cognitive compensatory training intervention for children with a history of pediatric cancer at the University of Michigan.
Study aims to enroll 10 children with a history of treatment for pediatric cancer, along with their caregiver.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Estimated)
20
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Cancer AnswerLine
- Phone Number: 1-800-865-1125
- Email: CancerAnswerLine@med.umich.edu
Study Locations
-
-
Michigan
-
Ann Arbor, Michigan, United States, 48109
- Recruiting
- University of Michigan
-
Contact:
- Cancer AnswerLine
- Phone Number: 800-865-1125
- Email: CancerAnswerLine@med.umich.edu
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
8 years to 18 years (Child, Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Patient between the ages of 8 and 18
- Patient has a history of pediatric cancer
- Patient is at least 6 months posttreatment completion
- Patient and caregiver are fluent in English, as intervention materials are only available in English at this time.
- Patient demonstrates deficits in attention and/or executive functioning as evidenced by either (a) performance below one standard deviation on at least one cognitive measure of attention or executive functioning, such as on the Conners Continuous Performance Test (CPT-3), Trail making Test A & B, Children's Category Test (CCT), and Wisconsin Card Sorting Test (WCST) and/or (b) executive functioning and attention problems are identified during screening with the research assistant.
Exclusion Criteria:
- Patient has a history of treatment for a pediatric brain tumor
- Patient has a history of traumatic brain injury or seizures
- Patient has a history of a developmental disorder (i.e., autism, intellectual disability), behavioral disorder (i.e., oppositional defiant disorder, conduct disorder), or mood disorder (i.e., disruptive mood dysregulation disorder) that would negatively interfere with patient's participation in the intervention.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Intervention
The intervention will include 5 weekly sessions (60-90 minutes each) of cognitive compensatory training (CCT) delivered virtually by a pediatric neuropsychologist.
|
The intervention will include 5 weekly sessions (60-90 minutes each) of cognitive compensatory training (CCT) delivered virtually by a pediatric neuropsychologist.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Determining satisfaction and perceived benefit from study intervention based off of change in results from the BRIEF-2 questionnaire from baseline to 6 weeks post trial entry
Time Frame: 6 weeks from trial entry
|
Completion of Study Questionnaire, BRIEF-2, at time of enrollment at after intervention completion.
|
6 weeks from trial entry
|
Determining satisfaction and perceived benefit from study intervention based off of change in results from the Conners 3 questionnaire from baseline to 6 weeks post trial entry
Time Frame: 6 weeks from trial entry
|
Completion of Study Questionnaire, Conners 3, at time of enrollment at after intervention completion.
|
6 weeks from trial entry
|
Determining satisfaction and perceived benefit from study intervention based off of change in results from the SMALSI-2 questionnaire from baseline to 6 weeks post trial entry
Time Frame: 6 weeks from trial entry
|
Completion of Study Questionnaire, SMALSI-2, at time of enrollment at after intervention completion.
|
6 weeks from trial entry
|
Determining satisfaction and perceived benefit from study intervention based off of change in results from the SPSI-R questionnaire from baseline to 6 weeks post trial entry
Time Frame: 6 weeks from trial entry
|
Completion of Study Questionnaires, SPSI-R , at time of enrollment at after intervention completion.
|
6 weeks from trial entry
|
Determining satisfaction and perceived benefit from study intervention based off of change in results from the PKEQ questionnaire from baseline to 6 weeks post trial entry
Time Frame: 6 weeks from trial entry
|
Completion of Study Questionnaires, PKEQ, at time of enrollment at after intervention completion.
|
6 weeks from trial entry
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Study completion
Time Frame: 6 weeks from trial entry
|
Possible factors contributing to study completion will be gathered from the History Questionnaire
|
6 weeks from trial entry
|
Clinical outcomes based off of response to the BRIEF-2 study questionnaire
Time Frame: 6 weeks from trial entry
|
Clinical outcomes of the intervention will also be summarized using empirically validated caregiver and child responses to the BRIEF-2 questionnaire
|
6 weeks from trial entry
|
Clinical outcomes based off of response to the Conners 3 study questionnaire
Time Frame: 6 weeks from trial entry
|
Clinical outcomes of the intervention will also be summarized using empirically validated caregiver and child responses to the Conners 3 questionnaire
|
6 weeks from trial entry
|
Clinical outcomes based off of response to the SMALSI-2 study questionnaire
Time Frame: 6 weeks from trial entry
|
Clinical outcomes of the intervention will also be summarized using empirically validated caregiver and child responses to the SMALSI-2 questionnaire
|
6 weeks from trial entry
|
Clinical outcomes based off of response to the SPSI-R study questionnaire
Time Frame: 6 weeks from trial entry
|
Clinical outcomes of the intervention will also be summarized using empirically validated caregiver and child responses to the SPSI-R questionnaire
|
6 weeks from trial entry
|
Clinical outcomes based off of response to the PKEQ study questionnaire
Time Frame: 6 weeks from trial entry
|
Clinical outcomes of the intervention will also be summarized using empirically validated caregiver and child responses to the PKEQ questionnaire
|
6 weeks from trial entry
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Kaitlin McCloskey, University of Michigan Rogel Cancer Center
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
February 17, 2023
Primary Completion (Estimated)
June 1, 2024
Study Completion (Estimated)
June 1, 2024
Study Registration Dates
First Submitted
January 9, 2023
First Submitted That Met QC Criteria
January 19, 2023
First Posted (Actual)
January 30, 2023
Study Record Updates
Last Update Posted (Estimated)
February 29, 2024
Last Update Submitted That Met QC Criteria
February 28, 2024
Last Verified
February 1, 2024
More Information
Terms related to this study
Other Study ID Numbers
- UMCC 2022.068
- HUM00218780 (Other Identifier: University of Michigan)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
IPD Plan Description
PI does not plan to share IPD
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pediatric Cancer
-
Emory UniversityNational Cancer Institute (NCI)Recruiting
-
Ann & Robert H Lurie Children's Hospital of ChicagoSilicon Valley Community FoundationUnknownCancer | Pediatric CancerUnited States
-
University of BirminghamCompletedCancer | Pediatric ALL | Pediatric Solid Tumor | Pediatric AMLUnited Kingdom, Australia, Netherlands
-
Alexandria UniversityCompletedPediatric Cancer | Invasive CancerEgypt
-
University of California, San DiegoNational Cancer Institute (NCI); Dana-Farber Cancer Institute; University of... and other collaboratorsNot yet recruiting
-
Immune Oncology Research InstituteRecruitingContinuous Infusion of First-Generation 5-HT3 Receptor Antagonists in Combination With DexamethasonePediatric CancerArmenia
-
Connecticut Children's Medical CenterThe Hospital for Sick ChildrenRecruitingPediatric CancerUnited States
-
Erin RowellRecruiting
-
Giselle ShollerRecruiting
-
Rigshospitalet, DenmarkUniversity of Copenhagen; Danish Cancer Society; Danish Child Cancer FoundationRecruitingPediatric CancerDenmark
Clinical Trials on Cognitive Compensatory Training
-
Taoyuan Psychiatric Center, Ministry of Health...Completed
-
University Hospital, MontpellierAssistance Publique - Hôpitaux de Paris; Assistance Publique Hopitaux De Marseille and other collaboratorsCompleted
-
University of California, San DiegoNational Institute of Mental Health (NIMH)UnknownSchizophrenia | Psychosis | Clinical High Risk | ProdromalUnited States, Mexico
-
Massachusetts General HospitalNational Institute of Mental Health (NIMH)Completed
-
University of California, San DiegoNational Institute of Mental Health (NIMH)CompletedSchizophreniaUnited States
-
Riphah International UniversityRecruitingCognitive ImpairmentPakistan
-
VA Office of Research and DevelopmentNot yet recruitingPost-Acute COVID-19 SyndromeUnited States
-
VA Office of Research and DevelopmentRecruitingPosttraumatic Stress DisorderUnited States
-
Oslo University HospitalThe Research Council of Norway; Sunnaas Rehabilitation Hospital; Norwegian Labour... and other collaboratorsCompletedCognitive Impairment | Brain Injuries, TraumaticNorway
-
Rosalind Franklin University of Medicine and ScienceNot yet recruiting